Nutra Pharma Corp (NPHC) Cash & Current Investments (2010 - 2026)

Nutra Pharma has disclosed Cash & Current Investments across 17 years of filings, most recently posting $267600.0 for Q2 2026.

• In Q2 2026, Cash & Current Investments rose 176.82% year-over-year to $267600.0; the TTM figure through Jun 2026 stood at $267600.0 (up 176.82% YoY), while the FY2025 annual figure was $29781.0, down 44.9% from the prior year.
• Cash & Current Investments came in at $267600.0 for Q2 2026 at Nutra Pharma, roughly flat from $267600.0 in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $267600.0 in Q1 2024 to a low of $6939.0 in Q1 2022.
• Average Cash & Current Investments over 5 years is $143855.9, with a median of $96669.0 recorded in 2025.
• Year-over-year, Cash & Current Investments sank 88.25% in 2025 and surged 751.06% in 2026.
• Over 5 years, Cash & Current Investments stood at $10448.0 in 2022, then surged by 236.91% to $35200.0 in 2023, then jumped by 53.54% to $54047.0 in 2024, then sank by 44.9% to $29781.0 in 2025, then jumped by 798.56% to $267600.0 in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $267600.0 in Q2 2026, $267600.0 in Q1 2026, and $29781.0 in Q4 2025.